These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32345708)

  • 61. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
    Trish E; Xu J; Joyce G
    Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medicare beneficiaries and free prescription drug samples: a national survey.
    Tjia J; Briesacher BA; Soumerai SB; Pierre-Jacques M; Zhang F; Ross-Degnan D; Gurwitz JH
    J Gen Intern Med; 2008 Jun; 23(6):709-14. PubMed ID: 18365289
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Factors associated with choice of pharmacy setting among DoD health care beneficiaries aged 65 years or older.
    Linton A; Garber M; Fagan NK; Peterson M
    J Manag Care Pharm; 2007 Oct; 13(8):677-86. PubMed ID: 17970605
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
    Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
    J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.
    Tadrous M; Greaves S; Martins D; Mamdani MM; Juurlink DN; Gomes T
    CMAJ Open; 2018 Mar; 6(1):E132-E138. PubMed ID: 29581101
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.
    Kale HP; Patel AM; Carroll NV
    J Manag Care Spec Pharm; 2018 Apr; 24(4):317-326. PubMed ID: 29578855
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.
    Chang HY; Kan HJ; Shermock KM; Alexander GC; Weiner JP; Kharrazi H
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1282-1290. PubMed ID: 32996394
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
    Egilman AC; Rome BN; Kesselheim AS
    JAMA; 2023 Apr; 329(15):1283-1289. PubMed ID: 37071095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Measuring economic impact of applying daily average consumption limits.
    Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids.
    Meissner BL; Moore WM; Shinogle JA; Reeder CE; Little JM
    J Manag Care Pharm; 2004; 10(3):226-33. PubMed ID: 15228372
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Access to prescription drugs for Medicare beneficiaries.
    Reschovsky JD; Felland LE
    Track Rep; 2009 Mar; (23):1-4. PubMed ID: 19320086
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
    King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
    J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Growth in prescription drug spending among insured elders.
    Thomas CP; Ritter G; Wallack SS
    Health Aff (Millwood); 2001; 20(5):265-77. PubMed ID: 11558712
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Difference in drug cost between private and public drug plans in Quebec, Canada.
    M C; A F; I C; M S; L B
    BMC Health Serv Res; 2022 Feb; 22(1):200. PubMed ID: 35164750
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.
    Daniel GW; Malone DC
    J Manag Care Pharm; 2007 Mar; 13(2):142-54. PubMed ID: 17330975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.